

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 07/28/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/010,167	12/10/2001	Igor B. Roninson	93,354-SS	8397	
20306	7590 07/28/2003				
MCDONNELL BOEHNEN HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE SUITE 3200			EXAMI	EXAMINER	
			KETTER, JAMES S		
CHICAGO, IL 60606			ART UNIT	PAPER NUMBER	
			1636	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)			
Office Action Summary		10/010,167	RONINSON ET AL.			
		Examiner	Art Unit			
		James S. Ketter	1636			
Period fo	The MAILING DATE of this communication or Reply	appears on the cover sheet with	the correspondence address			
A SH THE - Exte after - If the	ORTENED STATUTORY PERIOD FOR RE MAILING DATE OF THIS COMMUNICATIO insions of time may be available under the provisions of 37 CFF SIX (6) MONTHS from the mailing date of this communication; be period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory per	N. R 1.136(a) In no event, however, may a repl reply within the statutory minimum of thirty (ly be timely filed 30) days will be considered timely.			
- Any earn	ure to reply within the set or extended period for reply will, by stareply received by the Office later than three months after the made patent term adjustment. See 37 CFR 1.704(b).					
Status	D					
1)[Responsive to communication(s) filed on _					
2a)□	· —	This action is non-final.				
3)□	Since this application is in condition for all closed in accordance with the practice und					
	ion of Claims					
4)	Claim(s) <u>1-10</u> is/are pending in the applica					
🗀	4a) Of the above claim(s) is/are without	drawn from consideration.				
	Claim(s) is/are allowed.					
	Claim(s) <u>1-10</u> is/are rejected.					
	Claim(s) is/are objected to.					
	Claim(s) are subject to restriction an ion Papers	d/or election requirement.				
9)[The specification is objected to by the Exam	iner.				
10)🖸	The drawing(s) filed on 29 March 2002 is/are	e: a)⊠ accepted or b)⊡ objected	to by the Examiner.			
	Applicant may not request that any objection to	the drawing(s) be held in abeyand	ce. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a)□ approved b)□ disa	approved by the Examiner.			
	If approved, corrected drawings are required in	reply to this Office action.				
12)	The oath or declaration is objected to by the	Examiner.				
Priority ι	ınder 35 U.S.C. §§ 119 and 120					
13)	Acknowledgment is made of a claim for fore	eign priority under 35 U.S.C. § 1	119(a)-(d) or (f).			
a)	☐ All b) ☐ Some * c) ☐ None of:					
	1. Certified copies of the priority docume	ents have been received.				
	2. Certified copies of the priority documents have been received in Application No					
* 5	3. Copies of the certified copies of the papplication from the International See the attached detailed Office action for a	Bureau (PCT Rule 17.2(a)).	· ·			
14) [A	Acknowledgment is made of a claim for dome	estic priority under 35 U.S.C. §	119(e) (to a provisional application).			
) The translation of the foreign language Acknowledgment is made of a claim for dom					
Attachmen	_		-			
2) Notic	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of Info	mmary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)			
S. Patent and T	rademark Office					

Application/Control Number: 10/010,167

Art Unit: 1636

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1-4, 7 and 10 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-4, 7 and 8 of prior U.S. Patent No. 6,326,488. This is a double patenting rejection.

Despite the different wording of the instant claims as compared to the patented claims, the respective invention in each instance is the same, i.e., has the same scope.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-6, 8 and 9 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 21, 26, 41 and 88-91 of U.S. Patent No.

Art Unit: 1636

5,665,550. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are largely encompassed by the patented claims and vice versa.

Claims 1-6, 8 and 9 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 3 of U.S. Patent No. 6,083,746. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are largely encompassed by the patented claim and <u>vice versa</u>.

Claims 5 and 6 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 5 and 6 of U.S. Patent No. 6,326,488.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are largely encompassed by the patented claim and <u>vice versa</u>. As set forth below, it is not clear what the exact metes and bounds of the instant claims are. However, it would appear that there is at least substantial overlap, with the instant claims being of at least the same scope and possibly broader, thus encompassing the patented claims.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 10/010,167

Art Unit: 1636

Claims 5, 6, 8 and 9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Instant claims 5 and 6 recite the term "associated with sensitivity to chemotherapeutic drugs". However, it is unclear what this term means, as it is not apparent what kinds of functional or geometric associations are encompassed.

Claims 8 and 9 recite the limitation: "wherein the GSE comprises a portion of a gene otherwise not recognized as being responsible for said selectable phenotype." However, it is unclear what "not recognized" would have meant to one of skill in the art. How would the presence or absence of this limitation have been determined? Furthermore, who would be the person doing the recognizing? Still further, what would the coverage of the claim be after such recognition were made, e.g., by the practice of the claimed invention itself? Applicants should note that the preceding questions are not set forth facetiously, but rather, rhetorically, to show why the language in question cannot be definite under 35 USC § 112, second paragraph. In effect, Applicants are claiming an invention with the limitation or proviso that only those embodiments not already known in the art are encompassed.

Certain papers related to this application may be submitted directly to the Examiner by facsimile transmission at (703) 746-5155. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993)(see 37 CFR ' 1.6(d)). To send the facsimile to the Art Unit instead, the Art

Page 5

Application/Control Number: 10/010,167

on Control Number: 10/010,

Art Unit: 1636

Unit 1636 Fax number is (703) 305-7939. NOTE: If Applicant does submit a paper by fax to this number, the Examiner must be notified promptly, to ensure matching of the faxed paper to the application file, and the original signed copy should be retained by Applicant or Applicant's representative. (703) 308-4242 or (703) 305-3014 may be used without notification of the Examiner, with such faxed papers being handled in the manner of mailed responses. Applicant is encouraged to use the latter two fax numbers unless immediate action by the Examiner is required, e.g., during discussions of claim language for allowable subject matter. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the Examiner with respect to the examination on the merits should be directed to James Ketter whose telephone number is (703) 308-1169. The Examiner normally can be reached on M-F (9:00-6:30), with alternate Fridays off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Remy Yucel, can be reached at (703) 305-1998.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

Jsk

July 23, 2003

JAMES KETTER
PRIMARY EXAMINER